News

Regular exercise improves fitness in adults with cystic fibrosis (CF), and treatment with Kaftrio — a combination of elexacaftor, tezacaftor, and ivacaftor that’s marketed as Trikafta in the U.S. — may help patients engage more in higher-intensity physical activity, a German study suggests. The study, “Effects of…

The events slated for this year’s Cystic Fibrosis Awareness Month aim to celebrate the accomplishments, milestones, and hopes of those in the cystic fibrosis (CF) community. During May, U.S. and international organizations are encouraging people with CF to share their experiences and challenges, helping others picture what the future…

People with diabetes related to cystic fibrosis (CF) who had better long-term sugar control were more fit, a study found, suggesting that keeping blood sugar within normal limits may help improve the ability to exercise. The study, “The association between dysglycaemia and exercise capacity in cystic fibrosis,” was…

Treating expectant mothers with CFTR modulators may help to reduce the risk of intestinal complications for babies with cystic fibrosis (CF), according to a small real-world study from France. “We hope that such a study, merged with other international programmes, will also provide support for the European Medicines…

Children and adolescents with cystic fibrosis (CF) treated with Kaftrio, marketed as Trikafta in the U.S., experienced increases in the fat-soluble vitamins D and A for up to one year, according to a study from Spain. Treatment reduced the proportion of participants with vitamin D and vitamin A…

Kaftrio (elexacaftor/tezacaftor/ivacaftor), branded as Trikafta in the U.S., may help clear the nasal passages and surrounding air-filled cavities, known as sinuses, in children and adolescents with cystic fibrosis (CF), according to a real-world study from France. In the MODUL-CF study (NCT04301856), which involved 391 children and adolescents…

Undergraduate and graduate students in the U.S. who have cystic fibrosis (CF) are invited to apply for Abbvie‘s CF Scholarship program — the 2025 applications are now open, according to the pharmaceutical company’s website. Each year, the program selects 40 students for awards, with each given a…

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) contributed to a reduction in pulmonary exacerbations requiring hospitalization between 2018 and 2022 among children and young adults with cystic fibrosis (CF). That’s according to a recent study in the U.S. that also demonstrated that the proportion of hospitalized CF patients from minority groups,…

Pregnancy does not negatively impact survival or lung function in women with cystic fibrosis (CF) and, in fact, may be associated with a lower risk of death, according to a U.S. study that compared CF women who had been pregnant with those who had never been pregnant. No significant…

The European Commission has approved a label expansion for Kaftrio in combination with Kalydeco (ivacaftor) to treat cystic fibrosis (CF) caused by a wider range of mutations. The decision follows a positive endorsement by the Committee for Medicinal Products for Human Use, a branch of the…